- Scope of the procurement
- Lot 1 – One site to cover the NHS England population in the East of England
- Lot 2 - Two sites to cover the NHS England population in London
- Lot 3 – One site to cover the NHS England population in the Midlands
- Lot 4 – One site to cover the NHS England population in the North East of Englan
- Lot 5 – One site to cover the NHS England population in the North West of Englan
- Lot 6 – One site to cover the NHS England population in the South East of Englan
- Lot 7 - One site to cover the NHS England population in the South West of Englan
Section one: Contracting authority
one.1) Name and addresses
NHS England
1st Floor, Quarry House, Quarry Hill
Leeds
LS2 7UE
Contact
Josselin Canevet
Country
United Kingdom
Region code
UKE - Yorkshire and the Humber
Internet address(es)
Main address
Buyer's address
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
https://health-family.force.com/s/Welcome
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
https://health-family.force.com/s/Welcome
Tenders or requests to participate must be submitted to the above-mentioned address
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at
https://health-family.force.com/s/Welcome
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Provision of Haemophilia Advanced Therapy Medicinal Product (ATMP) Treatment Hubs
Reference number
C153405
two.1.2) Main CPV code
- 85100000 - Health services
two.1.3) Type of contract
Services
two.1.4) Short description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of
NHS England (referred to as the Commissioner), is inviting suitably qualified and
experienced providers to respond to this invitation to tender (ITT) exercise to commission
haemophilia Advanced Therapy Medicinal Product (ATMP) treatment hubs.
The haemophilia ATMP treatment hub allocation model is as follows:
Lot 1 – One site to cover the NHS England population in the East of England
Lot 2 - Two sites to cover the NHS England population in London
Lot 3 – One site to cover the NHS England population in the Midlands
Lot 4 – One site to cover the NHS England population in the North East of England and
Yorkshire
Lot 5 – One site to cover the NHS England population in the North West of England
Lot 6 – One site to cover the NHS England population in the South East of England
Lot 7 - One site to cover the NHS England population in the South West of England
Please note that providers must be located in the defined geographical catchment area(s) that they are interested in providing services to.
two.1.5) Estimated total value
Value excluding VAT: £1,000,000
two.1.6) Information about lots
This contract is divided into lots: Yes
Tenders may be submitted for one lot only
Maximum number of lots that may be awarded to one tenderer: 1
two.2) Description
two.2.1) Title
Lot 1 – One site to cover the NHS England population in the East of England
Lot No
1
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKH - East of England
two.2.4) Description of the procurement
The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
• the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner’s public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP
treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
16 December 2023
End date
15 December 2031
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 2 - Two sites to cover the NHS England population in London
Lot No
2
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKI - London
two.2.4) Description of the procurement
The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
• the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner’s public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP
treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
16 December 2023
End date
15 December 2031
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 3 – One site to cover the NHS England population in the Midlands
Lot No
3
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKF - East Midlands (England)
two.2.4) Description of the procurement
The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
• the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner’s public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP
treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
16 December 2023
End date
15 December 2031
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 4 – One site to cover the NHS England population in the North East of Englan
Lot No
4
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKC - North East (England)
two.2.4) Description of the procurement
The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
• the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner’s public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP
treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
16 December 2023
End date
15 December 2031
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 5 – One site to cover the NHS England population in the North West of Englan
Lot No
5
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKD - North West (England)
two.2.4) Description of the procurement
The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
• the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner’s public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP
treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
16 December 2023
End date
15 December 2031
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 6 – One site to cover the NHS England population in the South East of Englan
Lot No
6
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKJ - South East (England)
two.2.4) Description of the procurement
The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
• the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner’s public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP
treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
16 December 2023
End date
15 December 2031
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 7 - One site to cover the NHS England population in the South West of Englan
Lot No
7
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKK - South West (England)
two.2.4) Description of the procurement
The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
• the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner’s public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP
treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
16 December 2023
End date
15 December 2031
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section three. Legal, economic, financial and technical information
three.1) Conditions for participation
three.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers
List and brief description of conditions
As detailed within the ITT documents
three.1.2) Economic and financial standing
Selection criteria as stated in the procurement documents
three.1.3) Technical and professional ability
Selection criteria as stated in the procurement documents
three.2) Conditions related to the contract
three.2.2) Contract performance conditions
As detailed within the ITT documents
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.2) Time limit for receipt of tenders or requests to participate
Date
5 May 2023
Local time
12:00pm
four.2.4) Languages in which tenders or requests to participate may be submitted
English
four.2.6) Minimum time frame during which the tenderer must maintain the tender
Duration in months: 4 (from the date stated for receipt of tender)
four.2.7) Conditions for opening of tenders
Date
5 May 2023
Local time
12:00pm
Section six. Complementary information
six.1) Information about recurrence
This is a recurrent procurement: No
six.4) Procedures for review
six.4.1) Review body
NHS Arden and GEM CSU
Francis Crick House
Northampton
NN3 6BJ
Country
United Kingdom
Internet address
https://www.ardengemcsu.nhs.uk/
six.4.2) Body responsible for mediation procedures
NHS Arden and GEM CSU
Francis Crick House
Northampton
NN3 6BJ
Country
United Kingdom
Internet address
https://www.ardengemcsu.nhs.uk/
six.4.4) Service from which information about the review procedure may be obtained
NHS Arden and GEM CSU
Francis Crick House
Northampton
NN3 6BJ
Country
United Kingdom